EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
To examine whether the addition of nivolumab, a monoclonal antibody specific for human programmed death-1 (PD-1) receptor expressed on T cells, after chemoradiation can provide a survival benefit in patients with locally advanced high-risk anal cancer
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 832501
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
